What were Purple Biotech’s (NASDAQ:PPBT) net income and net loss for Q1 2026?

Purple Biotech reported a narrowed net loss of $0.1 million for Q1 2026. The company’s adjusted operating loss and adjusted net loss were both $2.1 million, with non-operating finance income helping offset the deficit.

How did non-operating income impact Purple Biotech’s Q1 2026 results?

Net finance income of $2.2 million significantly cushioned the company’s bottom line, reducing the net loss to $0.1 million and stabilizing financial performance despite operational losses.

What were Purple Biotech’s key operational expenditures in Q1 2026?

Operational spending included $1.2 million on research and development (R&D) and $1 million on general and administrative (G&A) expenses, reflecting continued investment in its immunotherapy pipeline.

How much cash did Purple Biotech have at the end of Q1 2026?

The company ended Q1 2026 with $6.4 million in cash, cash equivalents, and short-term bank deposits. Management indicated that this capital provides sufficient runway for planned operations through 2027.

What clinical milestones did Purple Biotech achieve in Q1 2026?

Operational progress was highlighted by new data from the CAPTN-3 platform, which employs masking technology to selectively activate therapies at tumor sites. Preclinical evaluations of IM1240, a tri-specific antibody targeting the 5T4 tumor-associated antigen, showed consistent anti-tumor activity across treatment-resistant patient-derived samples.

Purple Biotech narrows Q1 net loss as cancer pipeline progresses

Written by Mahathir BayenaPublished May. 15 2026Last Updated May. 15 2026

Purple Biotech (NASDAQ:PPBT) reported its financial and operational results for the first quarter of 2026, highlighting clinical milestones within its immunotherapy pipeline and a stabilized bottom line supported by non-operating income.

The Rehovot, Israel-based clinical-stage company posted a narrowed net loss of $0.1 million for the three months ended March 31, 2026.

The financial results were insulated by $2.2 million in net finance income, which balanced out an adjusted operating loss and adjusted net loss of $2.1 million each.

Operational expenditures for the quarter included $1.2 million directed toward research and development (R&D) alongside $1 million in general and administrative (G&A) outlays.

The biotech developer concluded the opening quarter with $6.4 million in cash, cash equivalents, and short-term bank deposits.

Management reiterated that its existing capital reserves provide a sufficient operational runway to fund planned clinical developments and overhead requirements into 2027.

Operationally, the quarter was anchored by new data from the company's CAPTN-3 platform, which utilizes masking technology to selectively activate therapies at tumor sites.

Preclinical evaluations for IM1240, a lead tri-specific antibody targeting the 5T4 tumor-associated antigen, demonstrated consistent anti-tumor activity across all tested, treatment-resistant patient-derived samples.